Introduction: Myasthenia gravis (MG) is an autoimmune disorder that affects the neuromuscular junction (NMJ) at the postsynaptic level. Ocular MG (OMG) is a subtype of MG where the weakness is clinically isolated to the EOMs, levator palpebrae and orbicularis oculi. There is not enough data on the clinico epidemiologic profile of OMG in the Indian population. Methods: During a period of one year (September 2007 to August 2008,out of 40 consecutive patients of MG 16 patients with a diagnosis of ocular MG presenting to the Neuromuscular clinic, Department of Neurology, at tertiary care referral were recruited for the study. All patients were followed up regularly for a minimum period of 3 years. Objectives: To describe the clinicoepidemiologic profile and outcome of OMG. Conclusion: Asymmetric ptosis and diplopia are the commonest manifestations in ocular myasthenia. Steroid is mostly needed in OMG.
Introduction
Myasthenia gravis (MG) is a potentially lethal, but treatable autoimmune disorder affecting the neuromuscular junction (NMJ) with a bimodal age distribution (1) . MG is a postsynaptic disorder due to Acetylcholine receptor antibodies (AChR-Abs) or MuSK antibodies resulting in defective neuromuscular junction transmission and subsequent muscle weakness. Extra ocular muscles (EOMs) commonly get fatigued as they are fast fibres with a high frequency of synaptic firing. Ptosis and diplopia are the presenting symptoms of the disease in over 50% of MG patients (2) . Among them, 50-80% of these patients go on to develop the generalized disease (3) . Generalization will occur in 90% within the first 2 years after ocular symptoms begin (4) . Ocular myasthenia gravis (OMG) remains restricted to ocular muscles beyond one year with 50% being seropositive for AChR-Abs (5, 6) . One-quarter of patients with MG in India have OMG (1) . OMG can mimic cranial nerve palsies, gaze palsies, internuclear ophthalmoplegia, and blepharospasm (7) . We do not have enough literature on the OMG from India. Hence, our objective is to look at the clinical and epidemiological profile of OMG and its shortterm prognosis.
Methods
We prospectively enrolled consecutive patients with OMG from September 2007 to August 2008 attending the Neuromuscular Clinic, Department of Neurology, Government Medical College, Trivandrum, Kerala, India. We diagnosed OMG based on history, clinical examination including bedside fatigability tests, supported by one or more of the following tests: ice pack test (8) , neostigmine test, and repetitive nerve stimulation (RNS) test suggestive of the postsynaptic defect. We used a train of 10 supramaximal stimuli, at a rate of 3 per second for RNS from orbicularis oculi using Neuro Quest Nichole machine. A decrement of more than 10% from the first to the fourth compound muscle action potential responses were considered positive. Post-exercise facilitation and post-exercise exhaustion were studied after one minute isometric exercise. We also did AChR antibody testing (Radioimmunoassay) and HRCT of the thorax with contrast.
Patients with onset at birth (Congenital myasthenia), family history (Familial Myasthenia) and RNS suggestive of presynaptic disease were excluded. We documented the duration of the illness, the clinical manifestation of the condition (9) and treatment received. Symptomatic treatment with 60 mg of pyridostigmine thrice a day titrated based on its effects and adverse effects to a maximum dose of 60mg four hourly (10) . We added prednisolone in an initial dose of 40 -60 mg if there is no symptomatic improvement in two weeks. Once there is an effective response for 2 to 4 weeks we started tapering prednisolone by 5-10 mg each month. We followed up these patients till August 2011 looking progression to generalized MG, crisis, remission and death. For patients who progressed to generalized MG, we added an immunomodulatory drug like azathioprine and subjected them to thymectomy.
Results
We recruited 40 patients with MG during the study period out of which 16 patients had OMG. OMG patients had a mean age of 42.69(SD 13.81) (range 18-65) years, a male: female ratio of 0.8:1 and a mean follow up of 3.7 years(2.1). Males had a mean age of 41 (11.26 
Discussion
The mean age of OMG was 42.69 years. Even though the mean age of patients with OMG was similar to the study by Kupersmith (11) , seropositive patients had earlier age of onset compared to seronegative OMG patients. We observed slight female preponderance unlike the male dominance reported by Kupersmith. We observed Acetylcholine receptor antibody seropositivity in 56.25% of OMG patients in the present study similar to the experience in other studies (12) . The only one patient who progressed to generalized myasethenia had high titres of AchRantibodies(5.07nmol/L). Seronegativity was associated with milder disease (13) . Even though Kupersmith found seropositivity to be related to generalization of MG, higher antibody titres did not predict generalized MG (11) . Due to our small sample we couldn't relate antibody titre and generalization.
We documented unilateral ptosis to be a common initial manifestation, most often on the right side (72%). Bilateral ptosis was often asymmetric, with enhancement of ptosis on contralateral eye on lifting the ptotic eye. We often resorted to In this study lateral rectus(25%) is slightly more frequently involved than medial rectus (18.8%) (14) . In contrast Finelli et al observed medial rectus involvement followed by the superior rectus (15) . Decremental response in RNS is seen in only 33% of patients with OMG which is comparable with our study(31.3%). (16) . All the patients with ptosis alone went into remission spontaneously and they required symptomatic management with pyridostimine. Only 1 patients required prolonged steroid therapy for 6months and continued at lower dose for longer periods. In study by Kupersmithetal steroids were given in similar doses as ours to 61.7%,but they had continued steroids at lower dose for longer periods. Most patients with diplopia required immunomodulation with steroid and we could taper off steroids in a shorter period than the experience of Kupersmith. This suggests the need for studies to determine the duration of steroid therapy in OMG. Our study reiterates the fact that OMG is not associated with thymoma (11) and thymectomy may not be needed. In the majority of cases progression of OMG to its generalized form will occur within the first 2 years after ocular symptoms begin (17) . It is similar to our study where generalization occurred within 1 year of ocular symptoms
Conclusion
Asymmetrical ptosis and diplopia are the most common manifestations of OMG. Association of thymoma is very rare with OMG and thymectomy may not be needed. Acetylcholine esterase inhibitors is the initial treatment in all OMG. Immunomodulation has pivotal role in OMG with diplopia and only short term steroid is required Source of support in the form of grants Nil
